Neuroprotective implant for treatment of glaucoma in phase II trial

Here's the latest innovations at Neurotech Pharmaceuticals, Inc. 

Rich Small, CPA, CEO of Neurotech Pharmaceuticals, Inc., shares what's in the pipeline for retina, glaucoma therapies. 

Related Videos
© 2023 MJH Life Sciences

All rights reserved.